Sarah R. Walmsley

Sarah R. Walmsley

Auto-generated profile, based on publicly available information

Sarah R. Walmsley

Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2013 in Nature
Verified
Journal Article
Open access
PDF file
GTG. M. Tannahill
G. M. Tannahill
ACA. M. Curtis
A. M. Curtis
JAJ. Adamik
J. Adamik
EPE. M. Palsson-McDermott
E. M. Palsson-McDermott
AMA. F. McGettrick
A. F. McGettrick
Luke O'NeillLuke O'Neill
Luke O'Neill
Succinate is identified as a metabolite in innate immune signalling, which leads to enhanced interleukin-1β production during inflammation. The bacterial endotoxin lipopolysaccharide activates macrophages, as part of the innate immunity response, by inducing a shift from oxidative to glycolytic metabolism. Gillian Tannahill et al. show here that lipopolysaccharide increases levels of the tricarboxylic acid cycle intermediate succinate in macrophages through a metabolic process not previously reported in macrophages, the 'GABA shunt'. Succinate in turn drives the key pro-inflammatory cytokine interleukin-1β. Macrophages activated by the Gram-negative bacterial product lipopolysaccharide switch their core metabolism from oxidative phosphorylation to glycolysis1. Here we show that inhibition of glycolysis with 2-deoxyglucose suppresses lipopolysaccharide-induced interleukin-1β but not tumour-necrosis factor-α in mouse macrophages. A comprehensive metabolic map of lipopolysaccharide-activated macrophages shows upregulation of glycolytic and downregulation of mitochondrial genes, which correlates directly with the expression profiles of altered metabolites. Lipopolysaccharide strongly increases the levels of the tricarboxylic-acid cycle intermediate succinate. Glutamine-dependent anerplerosis is the principal source of succinate, although the ‘GABA (γ-aminobutyric acid) shunt’ pathway also has a role. Lipopolysaccharide-induced succinate stabilizes hypoxia-inducible factor-1α, an effect that is inhibited by 2-deoxyglucose, with interleukin-1β as an important target. Lipopolysaccharide also increases succinylation of several proteins. We therefore identify succinate as a metabolite in innate immune signalling, which enhances interleukin-1β production during inflammation.

3 January 2005 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SWSarah R. Walmsley
Sarah R. Walmsley
CPCristin Print
Cristin Print
NFNeda Farahi
Neda Farahi
CPCarole Peyssonnaux
Carole Peyssonnaux
RJRandall S. Johnson
Randall S. Johnson
ECEdwin R. Chilvers
Edwin R. Chilvers
Neutrophils are key effector cells of the innate immune response and are required to migrate and function within adverse microenvironmental conditions. These inflammatory sites are characterized by low levels of oxygen and glucose and high levels of reductive metabolites. A major regulator of neutrophil functional longevity is the ability of these cells to undergo apoptosis. We examined the mechanism by which hypoxia causes an inhibition of neutrophil apoptosis in human and murine neutrophils. We show that neutrophils possess the hypoxia-inducible factor (HIF)-1α and factor inhibiting HIF (FIH) hydroxylase oxygen-sensing pathway and using HIF-1α–deficient myeloid cells demonstrate that HIF-1α is directly involved in regulating neutrophil survival in hypoxia. Gene array, TaqMan PCR, Western blotting, and oligonucleotide binding assays identify NF-κB as a novel hypoxia-regulated and HIF-dependent target, with inhibition of NF-κB by gliotoxin or parthenolide resulting in the abrogation of hypoxic survival. In addition, we identify macrophage inflammatory protein-1β as a novel hypoxia-induced neutrophil survival factor.

18 May 2015 in Nature
Verified
Journal Article
Open access
PDF file
VFVeronica Finisguerra
Veronica Finisguerra
GCGiusy Di Conza
Giusy Di Conza
MMMario Di Matteo
Mario Di Matteo
JSJens Serneels
Jens Serneels
SCSandra Costa
Sandra Costa
Massimiliano MazzoneMassimiliano Mazzone
Massimiliano Mazzone
Whether neutrophils exert an anti- or pro-tumorigenic function has remained controversial; now, expression of the receptor molecule MET in neutrophils is shown to be required for their ability to restrict tumour growth in several mouse cancer models, with potential implications for human cancer therapy. Whether neutrophils exert and anti- or pro-tumorigenic function has remained controversial. Massimiliano Mazzone and colleagues now show in several mouse models of cancer that expression of the receptor molecule MET in neutrophils is required for their ability to restrict tumour growth. MET expression in neutrophils is triggered by inflammatory signals, which can also be tumour-derived. MET activity is required for neutrophils to cross an activated endothelium to reach a tumour and to kill cancer cells. MET has been shown to be a therapeutic target in cancer cells which express MET, therefore the findings suggest that any beneficial effect is countered by inhibition of the anti-tumour neutrophil response, and the authors indeed demonstrate this in their mouse model. These findings are of relevance to therapeutic decisions based on anti-MET drugs, where it may be useful to monitor effects of the treatment in tumours showing a neutrophil response. Mutations or amplification of the MET proto-oncogene are involved in the pathogenesis of several tumours1,2,3,4, which rely on the constitutive engagement of this pathway for their growth and survival1,5. However, MET is expressed not only by cancer cells but also by tumour-associated stromal cells, although its precise role in this compartment is not well characterized6,7,8,9,10,11. Here we show that MET is required for neutrophil chemoattraction and cytotoxicity in response to its ligand hepatocyte growth factor (HGF). Met deletion in mouse neutrophils enhances tumour growth and metastasis. This phenotype correlates with reduced neutrophil infiltration to both the primary tumour and metastatic sites. Similarly, Met is necessary for neutrophil transudation during colitis, skin rash or peritonitis. Mechanistically, Met is induced by tumour-derived tumour necrosis factor (TNF)-α or other inflammatory stimuli in both mouse and human neutrophils. This induction is instrumental for neutrophil transmigration across an activated endothelium and for inducible nitric oxide synthase production upon HGF stimulation. Consequently, HGF/MET-dependent nitric oxide release by neutrophils promotes cancer cell killing, which abates tumour growth and metastasis. After systemic administration of a MET kinase inhibitor, we prove that the therapeutic benefit of MET targeting in cancer cells is partly countered by the pro-tumoural effect arising from MET blockade in neutrophils. Our work identifies an unprecedented role of MET in neutrophils, suggests a potential ‘Achilles’ heel’ of MET-targeted therapies in cancer, and supports the rationale for evaluating anti-MET drugs in certain inflammatory diseases.

26 February 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ARAnne L. Robertson
Anne L. Robertson
GHGeoffrey R. Holmes
Geoffrey R. Holmes
ABAleksandra N. Bojarczuk
Aleksandra N. Bojarczuk
JBJoseph Burgon
Joseph Burgon
CLCatherine A. Loynes
Catherine A. Loynes
SRStephen Renshaw
Stephen Renshaw
The proresolution therapeutic tanshinone IIA drives inflammation resolution by reverse migration.

1 January 2019 in Trends in Molecular Medicine
Verified
Journal Article
Open access
EWEmily R. Watts
Emily R. Watts
SWSarah R. Walmsley
Sarah R. Walmsley
Cells sense and respond to hypoxia through the activity of the transcription factor HIF (hypoxia-inducible factor) and its regulatory hydroxylases, the prolyl hydroxylase domain enzymes (PHDs). Multiple isoforms of HIFs and PHDs exist, and isoform-selective roles have been identified in the context of the inflammatory environment, which is itself frequently hypoxic. Recent advances in the field have highlighted the complexity of this system, particularly with regards to the cell and context-specific activity of HIFs and PHDs. Because novel therapeutic agents which regulate this pathway are nearing the clinic, understanding the role of HIFs and PHDs in inflammation outcomes is an essential step in avoiding off-target effects and, crucially, in developing new anti-inflammatory strategies.

21 July 2011 in Blood
Verified
Journal Article
Open access
PDF file
PEPhilip Elks
Philip Elks
FEFredericus J. van Eeden
Fredericus J. van Eeden
GDGiles Dixon
Giles Dixon
XWXingang Wang
Xingang Wang
Constantino Carlos Reyes-AldasoroConstantino Carlos Reyes-Aldasoro
Constantino Carlos Reyes-Aldasoro
SRStephen Renshaw
Stephen Renshaw
The oxygen-sensing transcription factor hypoxia-inducible factor-1α (HIF-1α) plays a critical role in the regulation of myeloid cell function. The mechanisms of regulation are not well understood, nor are the phenotypic consequences of HIF modulation in the context of neutrophilic inflammation. Species conservation across higher metazoans enables the use of the genetically tractable and transparent zebrafish (Danio rerio) embryo to study in vivo resolution of the inflammatory response. Using both a pharmacologic approach known to lead to stabilization of HIF-1α, and selective genetic manipulation of zebrafish HIF-1α homologs, we sought to determine the roles of HIF-1α in inflammation resolution. Both approaches reveal that activated Hif-1α delays resolution of inflammation after tail transection in zebrafish larvae. This delay can be replicated by neutrophil-specific Hif activation and is a consequence of both reduced neutrophil apoptosis and increased retention of neutrophils at the site of tissue injury. Hif-activated neutrophils continue to patrol the injury site during the resolution phase, when neutrophils would normally migrate away. Site-directed mutagenesis of Hif in vivo reveals that hydroxylation of Hif-1α by prolyl hydroxylases critically regulates the Hif pathway in zebrafish neutrophils. Our data demonstrate that Hif-1α regulates neutrophil function in complex ways during inflammation resolution in vivo.